Microbix Biosystems Inc.
MBX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.62% | -28.82% | -29.00% | -12.08% | -7.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.62% | -28.82% | -29.00% | -12.08% | -7.44% |
| Cost of Revenue | -11.12% | -13.49% | -15.11% | -9.14% | -14.33% |
| Gross Profit | -51.85% | -40.83% | -38.02% | -14.29% | -1.64% |
| SG&A Expenses | 3.18% | 5.73% | -7.84% | -6.82% | -12.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.25% | -4.29% | -9.79% | -6.71% | -11.56% |
| Operating Income | -322.26% | -241.16% | -135.18% | -65.14% | 61.53% |
| Income Before Tax | -436.14% | -307.56% | -162.12% | -103.40% | -58.69% |
| Income Tax Expenses | -136.68% | -136.68% | -136.68% | -- | -- |
| Earnings from Continuing Operations | -465.41% | -321.07% | -163.20% | -106.34% | -62.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -465.41% | -321.07% | -163.20% | -106.34% | -62.36% |
| EBIT | -322.26% | -241.16% | -135.18% | -65.14% | 61.53% |
| EBITDA | -192.35% | -148.14% | -94.91% | -39.91% | 36.60% |
| EPS Basic | -462.20% | -319.80% | -162.23% | -105.47% | -62.56% |
| Normalized Basic EPS | -429.82% | -304.35% | -160.48% | -98.39% | 72.73% |
| EPS Diluted | -477.50% | -329.29% | -165.96% | -107.30% | -62.96% |
| Normalized Diluted EPS | -429.82% | -304.35% | -160.48% | -98.39% | 72.73% |
| Average Basic Shares Outstanding | 0.47% | 1.14% | 0.11% | 1.46% | 0.65% |
| Average Diluted Shares Outstanding | -0.04% | 0.57% | -0.22% | 1.39% | 0.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |